Good day,
Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Before we send you your first edition, please take a moment to confirm your subscription below. We will not be able to send your newsletter until you confirm your subscription.
Confirm Your Subscription Here
The Earnings360 Team
Just For You Growth Picks: 3 Low-Cost Stocks That Could Double in ValueWritten by Chris Markoch. Published 10/27/2025. 
Key Points - Three undervalued growth stocks trading under $50 could deliver major upside if market conditions strengthen in 2026.
- Equinox Gold, Birkenstock, and Immunocore each carry analyst price targets suggesting 50% to 100% potential gains.
- Rising institutional interest, improving earnings, and biotech innovation make these stocks compelling buy-and-hold opportunities.
Many stocks appear overvalued, which can make it difficult for investors to find names with the potential to double. Penny stocks (i.e., stocks trading below $5) are often suggested, but they typically suit only the most risk-tolerant, nimble investors. There are still opportunities. One way to find them is to consider analyst sentiment. Analysts don't always get it right, but they often have access to data and company resources that retail investors do not. Their views are therefore a useful part of due diligence. With that in mind, here are three stocks trading for less than $50 per share that analysts see as having meaningful upside. While analysts aren't necessarily forecasting doubles for each, their consensus price targets are close enough that a favorable economic backdrop could push them to double. Equinox Gold: Gold's Momentum Could Keep Running Equinox Gold Corp. (NYSEAMERICAN: EQX) is a Canadian gold miner. As of Oct. 27, EQX is up about 100% year-to-date. Analysts give the stock a consensus price target of $26, implying a gain of more than 149% from current levels. Equinox is essentially a play on rising gold prices. Many analysts view mining stocks like EQX as an efficient way for equity investors to benefit from higher gold. The most bullish forecasts see the spot price of gold reaching $5,000 before the end of 2025, with further upside in 2026. Higher gold prices would materially improve Equinox's margins and profitability. The main risk is a reversal in the gold trade. Institutional ownership of EQX is only 38%, but it has been climbing sharply over the past 12 months and has trended upward for more than two years. Birkenstock: A Consumer Stock Ready to Rebound It's been a challenging year for consumer discretionary stocks, including Birkenstock Group AG (NYSE: BIRK). BIRK is down about 25% in 2025, but that decline may reflect broader retail-sector weakness rather than the company's fundamentals. Year-over-year revenue and earnings are both higher, with double-digit revenue growth across segments and channels. Analysts forecast earnings growth of more than 26% over the next 12 months, which is consistent with the company's forward price-to-earnings (P/E) ratio of roughly 23x. BIRK also has a relatively high short interest of around 17%, though that figure has fallen in the last month. That could be positive in two ways: it suggests short sellers may be losing conviction, and it still leaves the potential for a short squeeze if the stock rallies sharply. Analysts give BIRK a consensus price target of $68.38, implying about 58% upside. The company reports third-quarter results on Dec. 17, and strong holiday sales could help lift the stock into 2026. Immunocore: Biotech With Breakthrough Potential Immunocore plc (NASDAQ: IMCR) is a biotechnology company developing cancer treatments using T-cell technology. As of August 2025, the company has one drug that has successfully completed clinical trials and three candidates in or entering Phase 3 trials. Biotech stocks are often singled out for their potential to double: many firms remain at the clinical stage, and a single successful drug can dramatically change a company's outlook. Immunocore is beginning to generate measurable revenue and may be on a path toward profitability. Analysts give IMCR a consensus price target of $61. On Oct. 22, HC Wainwright reiterated a Buy rating and set a $100 target. Not all analysts share that optimism—Weiss Research has a Sell rating, arguing that much of the stock's growth may already be priced in.
| 
